This early-phase study aimed to test a new vaccine called KSD-201 in people with advanced clear cell renal cell carcinoma whose cancer had stopped responding to standard treatments. The vaccine uses the patient's own immune cells to try to fight the cancer. However, the trial was…
Phase: EARLY_PHASE1 • Sponsor: Kousai Bio Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:30 UTC